Health Care

Price Target Review: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA)

0 33

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) surged +2.48% and closed the trade at $ 23.60. The company recorded a trading capacity of 1.61 million shares above its three months average daily volume of 1.09 million shares. During the last trade, shares reached to high price of $24.36 and touched the low price of $23.29. The stock’s 50-day moving average is noted at $23.55 and its 200-day moving average is stands at $24.68.

Additionally, the companyhas EPS of -4.45. The company has market capitalization of $1.33B.

Currently Portola Pharmaceuticals, Inc. (PTLA) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “3″ Analysts”. “0” rated “Sell” for the company. “3” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $28.40 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $40.00 however minimum price target advised by analysts is $24.00. The Median price target for the stock is measured at $25.00.

Presently, Analysts decided consensus EPS estimate of $-1.10 for present quarter and one month ago projected EPS estimate was at $-1.07. If we take a look at back 3 month ago, consensus EPS estimate was $-1.23.

A current consensus EPS estimate for next quarter is at $-1.11 and 3 month ago EPS forecast was $-1.42. Have a look at back 1 month ago, consensus EPS forecast was seen at $-1.21.

For current fiscal year, most recent EPS estimate is set at $-4.42 based on Analyst consensus and three month ago consensus EPS opinions was at $-5.18. During period one month ago, consensus EPS forecast was decided at $-4.59.

A current consensus EPS projection for next fiscal year is observed at $-3.53 and one month ago consensus EPS forecast was at $-3.42. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-3.40 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 4 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 2 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 0 announced “Overweight Rating”. 2 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.